Home
About Rico
Company Profile
Development History
Corporate culture
Company environment
Company Honors
News
Company News
Industry Trends
Services
Cooperation
Partner
Contact Us
Policy
Join us
Social Recruitment
Campus Recruitment
CN
EN
National policy
11-10
Rico International (Beijing) Medicine Technology Co., Ltd. was established in 2020.
Rico International (Beijing) Medicine Technology Co., Ltd. was established in 2020. It is composed of a group of accomplished and highly contributing pharmaceutical experts, scholars, and business management professionals in the pharmaceutical and healthcare fields. The company aims to assist domestic and international pharmaceutical enterprises in product introduction, technology acquisition, and market expansion; to bring global pharmaceutical and healthcare products and technologies into China, enabling Chinese consumers to access cutting-edge and high-quality medicines from around the world, thereby benefiting the Chinese people; and at the same time, to export Chinese pharmaceutical and healthcare products and technologies to overseas counterparts, benefiting all humanity.
10-09
Announcement by the National Medical Products Administration on the Release of the Guiding Principles for Quality Agreements for Contract Manufacturing of Pharmaceuticals (2020 Edition) (No. 107 of 2020)
To implement the relevant provisions of the Drug Administration Law and further strengthen the supervision and management of drug production, the National Medical Products Administration has developed the “Guidelines for Quality Agreements on Contract Manufacturing of Drugs (2020 Edition),” which are intended to guide and supervise marketing authorization holders and contract manufacturing enterprises in fulfilling their obligations to ensure drug quality. These guidelines are hereby released and shall take effect from the date of their publication.
03-30
Drug Registration Management Measures
The “Administrative Measures for Drug Registration” were reviewed and approved at the 1st Bureau Meeting of the State Administration for Market Regulation on January 15, 2020, and are hereby promulgated and shall take effect as of July 1, 2020.
12-20
Notice of the National Medical Products Administration on the Issuance of Guiding Principles for Conditional Approval of Medical Devices for Market Launch (No. 93 of 2019)
To implement the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Pharmaceuticals and Medical Devices" issued by the General Office of the CPC Central Committee and the General Office of the State Council, address clinical treatment needs for serious life-threatening diseases, and accelerate the review and approval process for relevant medical devices, the National Medical Products Administration has developed the Guiding Principles for Conditional Approval of Medical Devices for Market Launch (see attachment). These principles are hereby released.
07-30
Regulations on the Management of Medical Device Instructions and Labels
The “Regulations on the Management of Instructions for Medical Devices and Labels” were reviewed and adopted at the Bureau Meeting of the State Administration for Food and Drug Administration on June 27, 2014. They are hereby promulgated and shall take effect as of October 1, 2014.
Medical Device Registration and Management Measures
The “Administrative Measures for the Registration of Medical Devices” were reviewed and approved at the Bureau Meeting of the State Administration for Food and Drug Administration on June 27, 2014. They are hereby promulgated and shall take effect as of October 1, 2014.